We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
Read MoreHide Full Article
Altimmune, Inc. (ALT - Free Report) announced positive topline results from its interim analysis of the MOMENTUM phase II obesity study on lead pipeline candidate pemvidutide. The company’s stock plunged about 55% on Tuesday following the news. This is likely due to investor dissatisfaction in terms of side effects from treatment with pemvidutide, leading to a high rate of discontinuation of the study.
Pemvidutide is Altimmune’s novel, investigational, peptide-based glucagon-like peptide 1 (GLP-1)/glucagon dual receptor agonist being developed to treat obesity and non-alcoholic steatohepatitis (NASH).
In the past year, shares of Altimmune have plunged 27.9% compared with the industry’s 17.4% decline.
Image Source: Zacks Investment Research
Altimmune’s MOMENTUM phase II study enrolled approximately 320 subjects with obesity or overweight with at least one co-morbidity and without diabetes. The subjects were divided into four cohorts each receiving either 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. The interim analysis data was from 160 subjects who completed 24 weeks of treatment.
At the end of Week 24, it was observed that the subjects receiving pemvidutide achieved mean weight losses of 7.3%, 9.4% and 10.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.0%. 75% of the subject population comprising subjects with baseline body weight less than or equal to 115 kg, witnessed a mean weight loss of 8.2%, 10.6%, 11.9% and 0.8% at the 1.2 mg, 1.8 mg, 2.4 mg and placebo groups, respectively. 10% or more weight loss was observed in approximately 50% of the subjects while about 20% of subjects achieved 15% or more weight loss at Week 24 at the 1.8 mg and 2.4 mg doses.
A rapid reduction in waist circumference, used to measure visceral fat, and serum lips were also observed, including clinically meaningful reductions in blood pressure, achieved without meaningful increases in heart rate. The safety profile of the candidate was also well-maintained in the study. Adverse events included nausea, vomiting, diarrhea and constipation which were predominantly mild and moderate in severity.
However, a treatment discontinuation rate of 28.2% in subjects receiving the placebo and 24.0% in subjects receiving pemvidutide was observed in the first 16 weeks of treatment. Discontinuation of treatment with pemvidutide was mostly due to the adverse events observed.
If approved, the management believes pemvidutide to be an important treatment option for patients with obesity, especially those who are at risk of cardiovascular disease, liver disease, dyslipidemia and related conditions. The company expects to complete the 48-week MOMENTUM phase II obesity study in the fourth quarter of 2023. Altimmune also plans to initiate a phase II biopsy NASH study in mid-2023.
The company also announced the results of the candidate’s 12-week phase Ib study to treat obesity or overweight and type II diabetes.
In this study, 54 subjects, aged 18-65 years, were again divided into four cohorts receiving either 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks. Average weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses of pemvidutide, respectively, were observed over only 12 weeks of treatment.
Compared to the candidate, the placebo group experienced a mean weight gain of 0.8%. In the course of this study, glucose homeostasis was maintained throughout the 12 weeks of treatment, with no significant changes in fasting glucose or HbA1c and no adverse events related to hyperglycemia. No adverse events lead to study discontinuation in this case.
A few other stocks worth considering are Avalo Therapeutics (AVTX - Free Report) , Avita Medical (RCEL - Free Report) and EQRx , each carrying a Zacks Rank #2 (Buy) at present.
In the last 90 days, Avalo’s loss estimates for the year 2023 have narrowed from $3.62 to $2.57 per share. In the past year, shares of Avalo have plunged 72.8%.
AVTX beat estimates in two of the last three reported quarters, missing the mark on one occasion, delivering an average earnings surprise of 37.83%.
In the last 90 days, Avita’s loss estimates for the year 2023 have narrowed from $1.26 to 99 cents per share. In the past year, shares of Avita have plunged 77.2%.
RCEL beat estimates in three of the last four reported quarters, missing the mark on one occasion, delivering an average earnings surprise of 22.16%.
In the last 90 days, EQRx’s loss estimates for the year 2023 have narrowed from 71 cents to 58 cents per share. In the past year, shares of EQRx have fallen 49.2%.
EQRX beat earnings estimates in all the last four reported quarters clocking an average earnings surprise of 34.99%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Altimmune (ALT) Stock Down Despite Positive Obesity Study Data
Altimmune, Inc. (ALT - Free Report) announced positive topline results from its interim analysis of the MOMENTUM phase II obesity study on lead pipeline candidate pemvidutide. The company’s stock plunged about 55% on Tuesday following the news. This is likely due to investor dissatisfaction in terms of side effects from treatment with pemvidutide, leading to a high rate of discontinuation of the study.
Pemvidutide is Altimmune’s novel, investigational, peptide-based glucagon-like peptide 1 (GLP-1)/glucagon dual receptor agonist being developed to treat obesity and non-alcoholic steatohepatitis (NASH).
In the past year, shares of Altimmune have plunged 27.9% compared with the industry’s 17.4% decline.
Image Source: Zacks Investment Research
Altimmune’s MOMENTUM phase II study enrolled approximately 320 subjects with obesity or overweight with at least one co-morbidity and without diabetes. The subjects were divided into four cohorts each receiving either 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. The interim analysis data was from 160 subjects who completed 24 weeks of treatment.
At the end of Week 24, it was observed that the subjects receiving pemvidutide achieved mean weight losses of 7.3%, 9.4% and 10.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses, respectively, with the placebo group experiencing a mean weight loss of 1.0%. 75% of the subject population comprising subjects with baseline body weight less than or equal to 115 kg, witnessed a mean weight loss of 8.2%, 10.6%, 11.9% and 0.8% at the 1.2 mg, 1.8 mg, 2.4 mg and placebo groups, respectively. 10% or more weight loss was observed in approximately 50% of the subjects while about 20% of subjects achieved 15% or more weight loss at Week 24 at the 1.8 mg and 2.4 mg doses.
A rapid reduction in waist circumference, used to measure visceral fat, and serum lips were also observed, including clinically meaningful reductions in blood pressure, achieved without meaningful increases in heart rate. The safety profile of the candidate was also well-maintained in the study. Adverse events included nausea, vomiting, diarrhea and constipation which were predominantly mild and moderate in severity.
However, a treatment discontinuation rate of 28.2% in subjects receiving the placebo and 24.0% in subjects receiving pemvidutide was observed in the first 16 weeks of treatment. Discontinuation of treatment with pemvidutide was mostly due to the adverse events observed.
If approved, the management believes pemvidutide to be an important treatment option for patients with obesity, especially those who are at risk of cardiovascular disease, liver disease, dyslipidemia and related conditions. The company expects to complete the 48-week MOMENTUM phase II obesity study in the fourth quarter of 2023. Altimmune also plans to initiate a phase II biopsy NASH study in mid-2023.
The company also announced the results of the candidate’s 12-week phase Ib study to treat obesity or overweight and type II diabetes.
In this study, 54 subjects, aged 18-65 years, were again divided into four cohorts receiving either 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 12 weeks. Average weight losses of 4.4%, 6.1% and 7.7% at the 1.2 mg, 1.8 mg, and 2.4 mg doses of pemvidutide, respectively, were observed over only 12 weeks of treatment.
Compared to the candidate, the placebo group experienced a mean weight gain of 0.8%. In the course of this study, glucose homeostasis was maintained throughout the 12 weeks of treatment, with no significant changes in fasting glucose or HbA1c and no adverse events related to hyperglycemia. No adverse events lead to study discontinuation in this case.
Altimmune, Inc. Price and Consensus
Altimmune, Inc. price-consensus-chart | Altimmune, Inc. Quote
Zacks Rank and Stocks to Consider
Altimmune currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
A few other stocks worth considering are Avalo Therapeutics (AVTX - Free Report) , Avita Medical (RCEL - Free Report) and EQRx , each carrying a Zacks Rank #2 (Buy) at present.
In the last 90 days, Avalo’s loss estimates for the year 2023 have narrowed from $3.62 to $2.57 per share. In the past year, shares of Avalo have plunged 72.8%.
AVTX beat estimates in two of the last three reported quarters, missing the mark on one occasion, delivering an average earnings surprise of 37.83%.
In the last 90 days, Avita’s loss estimates for the year 2023 have narrowed from $1.26 to 99 cents per share. In the past year, shares of Avita have plunged 77.2%.
RCEL beat estimates in three of the last four reported quarters, missing the mark on one occasion, delivering an average earnings surprise of 22.16%.
In the last 90 days, EQRx’s loss estimates for the year 2023 have narrowed from 71 cents to 58 cents per share. In the past year, shares of EQRx have fallen 49.2%.
EQRX beat earnings estimates in all the last four reported quarters clocking an average earnings surprise of 34.99%.